OLFM4

PreclinicalBiologic

IInstitut Cancerologie de l'Ouest

OLFM4 is one of 24 biologic programs targeting Breast Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

Breast CancerPreclinical

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Halaven

Eisai

Preclinical

38 2

Adriamycin

GGynecologic Oncology Group

Preclinical

87 3

Cymbalta

Alnylam Pharmaceuticals

Preclinical

3 4

MS Contin

Merck & Co.

Preclinical

2 5

Zinecard

CChildren's Oncology Group

Preclinical

2 6

Spravato

WWim Janssens

Preclinical

2 7

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 8

Chirocaine

PPurdue Pharma LP

Preclinical

1 9

Nubain

AAultman Health Foundation

Preclinical

1 10

Aquasol E

NNational Eye Institute (NEI)

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Breast Cancer1 trial

Women at Risk of Breast Cancer and OLFM4

Active, not recruiting·IInstitut Cancerologie de l'Ouest·N/A·NCT02653105·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for OLFM4. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — OLFM4 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for OLFM4. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Institut Cancerologie de l'Ouest company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: IInstitut Cancerologie de l'Ouest

OLFM4

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News